A case of advanced mycosis fungoides with comprehensive skin and visceral organs metastasis: sensitive to chemical and biological therapy

AbstractMycosis fungoides is a common cutaneous T-cell lymphoma, which is usually characterized by chronic, indolence progression, with absence of typical symptoms in early stage, metastasis to lymph nodes, bone marrow and visceral organs in later stage and ultimately progression to systemic lymphoma. It can result in secondary skin infection which is a frequent cause of death. At present, no curative therapy existed. Therapeutic purpose is to induce remission, reduce tumor burden and protect immune function of patients. A case of patient with advanced severe mycosis fungoides receiving CHOP plus interferon α-2a was reported here, with disease-free survival of 7 months and overall survival of over 17.0 months, and current status as well as developments of mycosis fungoides were briefly introduced

Poly[[[silver(I)-μ-1,4-bis­[(imidazol-1-yl)meth­yl]benzene-κ2 N 3:N 3′-silver(I)-μ-1,4-bis­[(imidazol-1-yl)meth­yl]benzene-κ2 N 3:N 3′] 4,4′-diazenediyldibenzoate] dihydrate]

In the title compound, [Ag2(C14H14N4)2](C14H8N2O4)·2H2O, each of the two unique Ag+ ions is two-coordinated by two N atoms from two different 1,4-bis­[(imidazol-1-yl)meth­yl]benzene ligands in an almost linear fashion [N—Ag—N = 170.34 (10) and 160.25 (10)°]. The 4,4′-diazenediyldibenzoate anions do not coordinate to Ag. O—H⋯O hydrogen bonds stabilize the crystal structure

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese population. Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-tumor activity. The present data regarding first-line treatment with single agent gefitinib against non-small-cell lung cancer (NSCLC) in Chinese population are not sufficient.</p> <p>Purpose</p> <p>To assess the efficacy and toxicity of gefitinib in Chinese patients with advanced non-small-cell lung cancer (NSCLC), a study of single agent treatment with gefitinib in Chinese patients was conducted.</p> <p>Methods</p> <p>45 patients with advanced NSCLC were treated with gefitinib (250 mg daily) until the disease progression or intolerable toxicity.</p> <p>Results</p> <p>Among the 45 patients, 15 patients achieved partial response (PR), 17 patients experienced stable disease (SD), and 13 patients developed progression disease (PD). None of the patients achieved complete response (CR). The tumor response rate and disease control rate was 33% and 71.1%, respectively. Symptom remission rate was 72.5%, and median remission time was 8 days. Median overall survival and median progression-free survival was 15.3 months and 6.0 months, respectively. The main induced toxicities by gefitinib were skin rash and diarrhea (53.3% and 33.3%, respectively). The minor induced toxicities included dehydration and pruritus of skin (26.7% and 22.2%, respectively). In addition, hepatic toxicity and oral ulceration occurred in few patients (6.7% and 4.4%2, respectively).</p> <p>Conclusions</p> <p>Single agent treatment with gefitinib is effective and well tolerated in Chinese patients with advanced NSCLC.</p

Mogućnost korištenja sepiolita kao matrice katalizatora FCC

The effect of acid concentration, time and temperature of modification on the magnesium removal from sepiolite modified by hydrochloric acid, sulfuric acid and nitric acid and on its effectiveness as an active matrix for FCC catalysts, were investigated. The modified sepiolite was characterized by XRD, SEM and N2 adsorption. The results show that the removal of magnesium, specific surface area, and pore specific volume of modified sepiolite are improved with increasing acid concentration, treating time and treating temperature. Hydrochloric acid appears preferable to the modification of sepiolite. The suitable acid modification conditions of sepiolite for FCC catalysts are 80 for 2.5 h with 1 mol L-1 HCl acid, under which the removal of magnesium in sepiolite is 27 %. With the modified sepiolite as an active matrix for FCC catalysts, the specific surface area, pore specific volume and mesopore pore specific volume of the catalysts can increase effectively, the catalysts exhibit excellent heavy-metal resisting performance and better cracking properties as a result of the introduction of magnesium oxide from the modified sepiolite.U radu je istraživano djelovanje koncentracije kiseline, vremena i temperature modificiranja na uklanjanje magnezija iz sepiolita, kao i na djelotvornost aktivne matrice FCC-katalizatora pripravljenog korištenjem solne, sumporne i dušične kiseline. Modificirani sepiolit je bio karakteriziran rendgenskom difrakcijom praškastih uzoraka, pretražnom elektronskom mikroskopijom te adsorpcijom N2. Dobiveni rezultati ukazuju na povećanje uklanjanja magnezija, specifične površine i volumena pora modificiranog sepiolita s povišenjem koncentracije kiseline, vremena i temperature reakcije. Uvjeti pogodni za kiselinsko modificiranje sepiolita jesu 80 °C tijekom 2,5 sata te c(HCl) = 1,0 mol dm-3, pri čemu se postiže 27-postotno uklanjanje magnezija. Korištenjem modificiranog sepiolita kao aktivne matrice FCC katalizatora, povećana je specifična površina, volumen pora te volumen mezopora katalizatora. Također, tako pripravljeni katalizatori iskazuju odličnu otpornost na kontaminaciju teškim kovinama te bolja krekirajuća svojstva kao posljedicu uklanjanja magnezijeva oksida iz sepiolita

The Immune Factors Involved in the Pathogenesis, Diagnosis, and Treatment of Sjogren's Syndrome

Sjogren's syndrome (SS) is a systemic, autoimmune disorder characterized by salivary insufficiency and lymphocytic infiltration of the exocrine glands. Even though the mechanism of its pathology and progression has been researched ever since its discovery, the roles of different parts of immune system remain inconclusive. There is no straightforward and simple theory for the pathogenesis and diagnosis of Sjogren’s syndrome because of the multiple kinds and functions of autoantibodies, changing proportion of different T-lymphocyte subsets with the progression of disease, unsuspected abilities of B lymphocytes discovered recently, crosstalk between cytokines connecting the factors mentioned previously, and genetic predisposition that contributes to the initiation of this disease. On the other hand, the number of significant reports and open-label studies of B-cell depletion therapy showing clinical efficacy in sjogren’s syndrome has continued to accumulate, which provides a promising future for the patients. In a word, further elucidation of the role of different components of the immune system will open avenues for better diagnosis and treatment of SS, whose current management is still mainly supportive

Salaklar Derneği, Sözen'i yılın adamı seçti

Taha Toros Arşivi, Dosya No: 207-Nurettin-Gürol-Metin SözenUnutma İstanbul projesi İstanbul Kalkınma Ajansı'nın 2016 yılı "Yenilikçi ve Yaratıcı İstanbul Mali Destek Programı" kapsamında desteklenmiştir. Proje No: TR10/16/YNY/010

Comparison of two different starting dose of rhFSH in GnRH antagonist protocol for patients with normal ovarian reserve

ObjectiveTo evaluate different starting doses of recombinant human follicle-stimulating hormone (rhFSH) on pregnancy outcomes for patients with normal ovarian reserve during gonadotropin- releasing hormone antagonist (GnRH-ant) protocol-controlled ovarian stimulation of in vitro fertilization (IVF) cycles.MethodsIn this retrospective study, a total of 1138 patients undergoing IVF cycles following the GnRH-ant protocol were enrolled. Patients were divided into two groups according to the starting dose of rhFSH. 617 patients received a starting dose of rhFSH of 150 IU, and 521 patients received a starting dose of rhFSH of 225 IU. We compared demographic characteristics, ovarian stimulation and embryological characteristics, and pregnancy and birth outcomes between the two groups. Multivariate logistic regression analysis was performed to examine the possible effects of the known potential confounding factors on pregnancy outcomes.ResultsThe number of oocytes retrieved in the 150 IU rhFSH group was significantly lower than those in the 225 IU rhFSH group. There was no significant difference between the two groups referring to embryological characteristics. The proportion of fresh embryo transfer in the 150 IU rhFSH group was significantly higher than that in the 225 IU rhFSH group (48.30% vs. 40.90%), and there was no difference in the risk of ovarian hyperstimulation syndrome and pregnancy outcomes between the two groups.ConclusionsIn conclusion, the starting dose of rhFSH of 150 IU for ovarian stimulation has a similar pregnancy outcome as starting dose of rhFSH of 225 IU in GnRH-ant protocol for patients with normal ovarian reserve. Considering the potential cost-effectiveness and shorter time to live birth, the starting dose of rhFSH of 150 IU may be more suitable than 225 IU